Pharma's Almanac TV
PA TV
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Oncology
326 Articles Available
1
14
Can't find what you're looking for? Try our
advanced search
.
Oncology
Dozens of Non-Oncology Drugs Can Kill Cancer Cells
PR-M01-20-NI-031
Cancer Breakthrough
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
PR-M01-20-NI-026
Cancer Treatment
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer Patient
PR-M01-20-NI-020
Drug Development
LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
PR-M01-20-NI-003
Immunotherapy
NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Combination Immunotherapy in Triple Negative Breast Cancer
PR-M12-19-NI-022
Oncology
Simultaneous RNA and DNA Testing is More Effective than DNA Testing Alone
PAO-M12-19-NI-003
M&A
Merck to Acquire ArQule, Advancing Leadership in Oncology
PR-M12-19-NI-017
Photodynamic Therapy
Developing a Potential Cure for Bladder Cancer
PAP-Q4-19-CL-031
Bristol-Myers Squibb Announces Update for Patients with Resected High-Risk Melanoma and PD-L1 <1%
Drug Approval
Calquence Approved in the US for Adult Patients with Chronic Lymphocytic Leukemia
PR-M11-19-NI-037
Gene Therapy
Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
PR-M11-19-NI-032
Launch
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
PR-M11-19-NI-024
FDA Approval
Sandoz Receives FDA Approval for Oncology Supportive Care Biosimilar Ziextenzo™
PR-M11-19-NI-006
Strategic Collaboration
Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China
PR-M10-19-NI-048
Containment
Meeting the Need for Higher Containment
PAP-Q3-19-CL-025
Genomics Technology
Personalizing Cancer Treatment with Genomics Technology
PAP-Q3-19-CL-018
FDA Guidance
Updating Ethical Guidelines for Cancer Clinical Trials
PAP-Q3-19-NI-006
FDA Priority Review
[Fam-] Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment of Patients With HER2-positive Metastatic Breast Cancer
PR-M10-19-NI-025
Research
Viagra Helps Mobilize Bone Marrow Stem Cells for Transplantation in Mice
PR-M10-19-NI-018
Oncology
Blood Test Can Replace Invasive Biopsy for More Patients with Lung Cancer
PR-M09-19-NI-059
Liquid Biopsy
GRAIL Announces Positive New Data with Multi-Cancer Early Detection Blood Test from CCGA Study
PR-M09-19-NI-058
DataArt’s Healthcare & Life Sciences Practice Launches “SkinCareAI” Prototype App for Early Melanoma Detection
PR-M09-19-NI-054
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
PR-M09-19-NI-007
Collaboration
Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology
PR-M09-19-NI-002
1
14
»
